GlobalData on MSN
AtaCor raises $75m for trial of EV-ICD system
The US FDA study is intended to evaluate the system for treating life-threatening ventricular tachyarrhythmias.
Hosted on MSN
Implantable cardioverter defibrillators did not improve mortality in selected heart-attack patients
Prophylactic implantable cardioverter defibrillator therapy did not reduce mortality in patients with a prior myocardial infarction, persistent moderate left ventricular systolic dysfunction and ...
Prophylactic implantable cardioverter defibrillator therapy did not reduce mortality in patients with a prior myocardial infarction, persistent moderate left ventricular systolic dysfunction and ...
AtaCor Medical announced today that it entered a financing worth up to $75 million to support its U.S. FDA pivotal study.
AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management systems, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback